|1.||Barrett, Ronald W: 6 articles (09/2012 - 10/2004)|
|2.||Cundy, Kenneth C: 4 articles (01/2013 - 10/2004)|
|3.||Luo, Wendy: 4 articles (01/2013 - 10/2004)|
|4.||Bogan, Richard K: 3 articles (05/2015 - 06/2010)|
|5.||Warren, Samantha: 3 articles (12/2013 - 09/2012)|
|6.||Graff, Ole: 3 articles (12/2013 - 06/2013)|
|7.||Chen, Chao: 3 articles (12/2013 - 06/2013)|
|8.||Tovera, James: 3 articles (01/2013 - 02/2012)|
|9.||Lal, Ritu: 3 articles (01/2013 - 02/2012)|
|10.||Chen, Dan: 3 articles (07/2012 - 01/2011)|
|1.||Restless Legs Syndrome (Restless Legs)
12/01/2012 - "In the 12-week Patient Improvements in Vital Outcomes following Treatment (PIVOT) RLS I and II trials in adult patients with moderate to severe primary RLS (n > 500 total evaluable), once-daily gabapentin enacarbil 600 or 1,200 mg significantly improved mean International Restless Legs Scale (IRLS) total scores compared with placebo, with significantly higher investigator-rated Clinical Global Impression-Improvement (CGI-I) responder rates in gabapentin enacarbil groups than in placebo groups. "
11/01/2009 - "Gabapentin enacarbil at 1200 mg significantly improved restless legs syndrome symptoms compared with placebo. "
02/03/2009 - "XP13512 1,200 mg, taken once daily, significantly improved restless legs syndrome (RLS) symptoms compared with placebo and was generally well tolerated in adults with moderate to severe primary RLS."
12/01/2011 - "Gabapentin enacarbil is a new treatment for restless legs syndrome (RLS). "
01/01/2011 - "This open-label, multicenter, 52-week extension study (NCT00333359) assessed the long-term safety and efficacy of gabapentin enacarbil in subjects with moderate-to-severe primary restless legs syndrome (RLS). "
06/01/2014 - "Administering gabapentin enacarbil also improved the continuous leg pain that occurred in conjunction with the development of RLS. "
06/01/2014 - "This is the first report reporting the effects of gabapentin enacarbil for RLS and leg pain in a DLB patient with psychiatric symptoms. "
05/01/2015 - "Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil."
05/01/2014 - "Subgroup analysis on formulation of gabapentin showed that gabapentin enacarbil had similar efficacy of pain relief with other formulations while it may be superior to others in term of compliance and safety. "
01/01/2012 - "Additionally, gabapentin enacarbil may be recommended for patients with daily RLS symptoms that are less intense or are associated with pain as an alternative to dopamine agonists."
01/01/2013 - "Gabapentin enacarbil extended release for the treatment of postherpetic neuralgia in adults."
06/01/2013 - "A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748)."
12/01/2012 - "Oral gabapentin enacarbil is approved in adult patients for the treatment of moderate to severe primary restless legs syndrome (RLS) [featured indication] and the management of postherpetic neuralgia. "
07/01/2011 - "Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin."
12/01/2013 - "A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders."
01/01/2014 - "Although most clinical trials assessed gabapentin enacarbil at doses greater than 600 mg/day and demonstrated the overall safety and efficacy (defined as improvements in the coprimary endpoints of the international RLS rating scale [IRLS] total score and Clinical Global Impression-Improvement response), the US Food and Drug Administration approved the 600 mg once-daily dosage because doses higher than 600 mg/day were considered to provide no additional benefits and were associated with higher rates of adverse events, such as somnolence and dizziness. "
09/01/2011 - "The most commonly reported adverse events were dizziness (gabapentin enacarbil 20%, placebo 2%) and somnolence (gabapentin enacarbil 13%, placebo 2%). "
01/01/2010 - "The most frequently reported adverse events associated with gabapentin enacarbil are dizziness and somnolence, which are transient and of mild intensity. "
02/03/2009 - "The most commonly reported adverse events were somnolence (XP13512 27%, placebo 7%) and dizziness (XP13512 20%, placebo 5%), which were mild to moderate in intensity and generally remitted. "
02/01/2009 - "The most frequently reported adverse events were somnolence (XP13512 30.6%, placebo 2.8%) and dizziness (XP13512 27.8%, placebo 5.6%). "
|5.||Impulse Control Disorders (Kleptomania)
01/01/2014 - "The alpha-2-delta ligands, including gabapentin, gabapentin enacarbil, and pregabalin, are effective for RLS without known occurrence of augmentation or impulse control disorders, although sedation and dizziness can occur. "
02/01/2013 - "Calcium channel alpha-2-delta ligands (gabapentin, gabapentin enacarbil, and pregabalin) provide alternative therapies for RLS especially in patients with augmentation, impulse control disorders, or hypersomnia induced by dopamine agonists. "
|3.||Dopamine Agonists (Dopamine Agonist)
|5.||1- (((alpha- isobutanoyloxyethoxy)carbonyl)aminomethyl)- 1- cyclohexaneacetic acid
|6.||Dopamine Agents (Dopaminergic Agents)
|7.||Calcium Channels (Calcium Channel)
|1.||Drug Therapy (Chemotherapy)
|2.||Complementary Therapies (Alternative Medicine)